Treatment of relatively rare species nontuberculous pulmonary mycobacteriosis

Today, a treatment guide of relatively rare species nontuberculous mycobacteriosis (NTM) is required ever-increasing. Because, new species are discovered continuously with advanced nucleic identification technique and these results entered routine clinical practice. Secondly, under the influence of newly introduced bioactive drugs for treatment of RA, rare species NTM cases has been really increased. And although there have been over 150 species NTM, the right chemotherapy regimen is not uniform like as TB treatment, it should only rely on accumulated clinical experiences for each species respectively. Case series of relatively rare species NTM are rare enough in itself at a global level, therefor the treatment is also less evidence. However, the following two may be written definitely recommended. M. szulgai pulmonary disease chemotherapy is recommended with RFP, INH, EB chemotherapy includes 12 months of negative sputum cultures. M. fortuitum pulmonary disease should be given at least more than two sensitive drugs including new quinolone for to reach 12 months of negative sputum cultures. For other species, chemotherapy regimen and duration of treatment has not been established. In case of unspecified or unknown species mycobacteriosis, the chemotherapy regimen should be suggested the treatment of in relatively same group on Runyon classification.